New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
06:57 EDTBDSIBioDelivery Sciences risk/reward profile favorable, says William Blair
William Blair reiterates an Outperform rating on shares of BioDelivery Sciences ahead of the June 7 PDUFA date for Bunavail, the company's buprenorphine/naloxone sublingual film for the treatment of opioid addiction. The firm says the FDA has been focused on new therapies for opioid addiction given the current opioid-abuse crisis. It views the risk/reward for BioDelivery shares as favorable and has a $16 price target for the stock.
News For BDSI From The Last 14 Days
Check below for free stories on BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
08:44 EDTBDSIBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
September 8, 2014
08:52 EDTBDSIBioDelivery Sciences price target raised to $28 from $20 at Summer Street
Summer Street raised its price target for BioDelivery Sciences shares to $28 saying it left the company's analyst day on Friday incrementally more positive. The firm believes its sales estimates for Bunavail and BEMA Buprenorphine may prove to be conservative and reiterates a Buy rating on the stock.
September 3, 2014
05:23 EDTBDSIBioDelivery Sciences to host investor/analyst meeting
Investor/Analyst meeting to be held in New York on September 5 at 12 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use